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Abstract 
Purpose: To report the effective treatment of cystoid macular edema (CME) following 
complicated cataract surgery (resulting in Irvine-Gass syndrome) with a dexamethasone 
0.7-mg (Ozurdex) intravitreal implant.  
Methods: An interventional case report with optical coherence tomography (OCT) scans.  
Results: An 83-year-old Caucasian woman was suffering from CME following complicated 
cataract surgery on her left eye. She had undergone 3 intravitreal injections of 
dexamethasone 0.4 mg in the 3 months following the surgery without any improvement 
of visual function. Seven months after the cataract surgery, she received a single 
intravitreal injection of dexamethasone 0.7 mg (Ozurdex). Four weeks following the 
injection, her best-corrected visual acuity improved from 0.3 to 0.8. CME resolved with a 
reduction of central retinal thickness from 393 μm pre-Ozurdex injection to 212 μm post-
Ozurdex injection, as measured by OCT scan.  
Conclusion: Dexamethasone 0.7 mg (Ozurdex) has proven to be an effective treatment 
option in retinal vein occlusion and non-infectious uveitis. It can also be considered as 
off-label treatment in Irvine-Gass syndrome. 
 
Introduction 
Irvine-Gass syndrome, which describes vision loss after cataract surgery due to cystoid 
macular edema (CME), is still recognized as one of the most common causes of poor 
visual outcome following cataract surgery [1, 2]. Despite treatment options for Irvine-
Gass syndrome which include non-steroidal anti-inflammatory drugs, corticosteroids and Case Rep Ophthalmol 2011;2:319–322 
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acetazolamide, and new fields of clinical research including the use of anti-vascular 
endothelial growth factor agents, resistant cases of macular edema are common [3, 4]. 
Corticosteroids are potent anti-inflammatory agents that can counteract many of the 
pathological processes thought to play a role in the development of postoperative CME. 
Recently, a sustained-release dexamethasone implant (Ozurdex) has become available 
for the treatment of patients suffering from CME due to retinal vein occlusion and non-
infectious uveitis [5]. 
We report a case of CME resolution and significant improvement of visual function 
following the intravitreal injection of dexamethasone 0.7 mg in a patient with Irvine-Gass 
syndrome even after previous intravitreal therapy with dexamethasone 0.4 mg had been 
repeatedly unsuccessful. 
Case Report 
An 83-year-old Caucasian woman developed CME following complicated cataract surgery on her 
left eye in 2010 (fig. 1). She had undergone 3 intravitreal injections of dexamethasone 0.4 mg in the 
following 3 months without any improvement in visual acuity. Seven months after the cataract surgery, 
she presented for the first time at our clinic and received a single intravitreal injection of dexamethasone 
0.7 mg (Ozurdex) as off-label treatment. Four weeks following the injection, her best-corrected visual 
acuity (BCVA) improved from 0.3 to 0.8. The CME resolved with a reduction of central retinal 
thickness from 393 μm pre-Ozurdex injection to 212 μm post-Ozurdex injection, as measured by optical 
coherence tomography (OCT) scan (fig. 2). Her condition has been stable for at least 3 months now, as 
seen on the last examination, with BCVA 0.8 and resolved macular edema (fig. 3) in the treated eye. 
Discussion 
Current evidence suggests that the dexamethasone 0.7-mg implant (Ozurdex) is a 
favorable treatment option in patients with CME and vision loss due to retinal vein 
occlusion and non-infectious uveitis [6, 7]. In accordance with the case report presented 
here, a subgroup analysis of a clinical phase II study indicated that dexamethasone 0.7 mg 
might also be effective in patients suffering from Irvine-Gass syndrome following cataract 
surgery [8]. 
However, it is unknown whether the dexamethasone 0.7-mg implant could even 
effectively reduce CME in already pre-treated eyes that were refractory to previous 
intravitreous dexamethasone injections. Our case report indicates that Ozurdex 
effectively restores visual function and reduces CME in Irvine-Gass syndrome even 
though previously applied intravitreous treatment with 3 dexamethasone injections was 
unsuccessful. Similar to the results from Williams et al. [8], who reported a considerable 
functional improvement after treating Irvine-Gass patients with dexamethasone 0.7 mg, 
our patient improved from BCVA 0.3 pre-Ozurdex injection to BCVA 0.8 post-Ozurdex 
injection. 
A possible explanation for the inefficiency of previous intravitreal dexamethasone 
injections in the presented case could be the short half-life of unbound dexamethasone in 
the vitreous cavity [9]. This problem can be overcome by the currently available 
sustained-release dexamethasone implant. Case Rep Ophthalmol 2011;2:319–322 
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In conclusion, the dexamethasone implant (Ozurdex) might be an effective treatment 
option not only in retinal vein occlusion and non-infectious uveitis but can also be 
considered as off-label treatment in Irvine-Gass syndrome. 
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Fig. 1. OCT scan of CME following complicated cataract surgery. The infrared picture shows retinal 
localization. CME was refractory to treatment with 3 intravitreal injections of dexamethasone 0.4 mg. 
Central retinal thickness was 393 μm. 
 
 
 
Fig. 2. Resolved macular edema 4 weeks following an intravitreal injection of a dexamethasone 0.7-mg 
implant (Ozurdex). The infrared picture shows retinal localization. Central retinal thickness was 212 
μm. 
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Fig. 3. Follow-up examination 120 days after Ozurdex injection. The infrared picture shows retinal 
localization. Central retinal thickness was 210 μm. 
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